Illumina (ILMN – Analyst Report) Inc. is a biotech company that specializes in genetic sequencing. Using their resources, the company has mapped gene variations associated with health, disease, and drug responses. The company is a global leader in genomics.
Volume has been higher than usual for the stock today. There has been some selling activity associated with shares, as share prices were down 1% at the closing bell. This suggests that investors were bearish on ILMN going into the earnings report. It's worth noting that some higher ups within the company have sold a considerable amount of their shares in the last week.
Our consensus has been climbing up in the last 90 days, going from an EPS consensus of $0.75 to $0.78.
In the last week, Illumina's rank has gone from a Zacks Rank #3 (Hold), to a Zacks Rank #2 (Buy).
Earnings: Illumina posted earnings of $0.80 per share, beating our consensus of $0.78.
Revenue: The company posted revenues of $539 million, missing on our consensus of $543 million.
Key Stats: Revenues were 21% higher than they were in Q2 2014 ($448 million). Net income in Q2 2015 came in at $102.24 million, much higher than the $46.6 million Illumina posted in Q2 2014.
Stock Price: Shares are taking a beating in after hour trading. Shares have lost about 8% of their value since the closing bell, and are currently trading for $218.02.
